Press Releases

The Latest from 10x

10x Genomics appoints Mathai Mammen, M.D., Ph.D. to its Board of Directors

– Leading innovator in drug development brings more than three decades of biotechnology and pharmaceutical experience to the company’s Board of Directors –

PLEASANTON, Calif. – (August 23, 2017) – 10x Genomics, a company focused on enabling the mastery of biology by accelerating genomic discovery, today announced that Mathai Mammen, M.D., Ph.D. has been appointed to the company’s Board of Directors.

“I am delighted to welcome Dr. Mammen to our Board of Directors. He is a phenomenal scientist and leader with a great track record of establishing R&D programs and building commercially successful companies within the pharmaceutical and biotechnology industries,” said Serge Saxonov, co-founder and CEO of 10x Genomics. “10x aims to enable innovative discoveries in precision medicine. Dr. Mammen’s experience building companies and his expertise across the biotech landscape will be invaluable for helping us drive toward our vision.”

Dr. Mammen currently serves as global head, science and development at the Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to joining Janssen, he was senior vice president at Merck Research Laboratories, responsible for programs focused on cardiovascular, metabolic and renal diseases, as well as oncology/immuno-oncology and immunology.

Previous to Merck, Dr. Mammen led research and development at Theravance, a company he co-founded in 1997 based on his work at Harvard University. Under his leadership, the company nominated more than 30 development candidates in 17 years, created three approved products (Breo®, Anoro®, Vibativ®), as well as a pipeline containing 11 development-stage compounds and two additional assets that have successfully completed Phase 3 studies.

Dr. Mammen has authored more than 150 peer-reviewed publications and patents. He received his M.D. from the Harvard Medical School and Massachusetts Institute of Technology HST program and a Ph.D. in Chemistry from Harvard University, where he worked with George Whitesides. He received a BSc in Chemistry and Biochemistry from Dalhousie University in Halifax, Nova Scotia.

About 10x Genomics

10x Genomics is changing the definition of sequencing by providing an innovative genomics platform that dramatically upgrades the capabilities of existing sequencing technologies. This is achieved through a combination of new microfluidic science, chemistry and bioinformatics. By implementing GemCode Technology within the Chromium System, researchers can now, for the first time, find new structural variants, haplotypes and other valuable genomic information with comprehensive workflows for Single Cell, V(D)J, Genome, Exome and de novo Assembly applications that incorporate their pre-existing sequencing technologies.

Media Contact

Colin Sanford
Pure Communications
(415) 946-1094
[email protected]

Investor Contact

Matt Clawson
Pure Communications
(949) 370-8500
[email protected]